Education
About Us
Working with TipRanks
Follow Us
Invivyd (IVVD)
NASDAQ:IVVD
IVVD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.35 - $2.74
Previous CloseN/A
Volume606.77K
Average Volume (3M)2.11M
Market Cap
$100.28M
Enterprise ValueN/A
Total Cash (Recent Filing)$69.35M
Total Debt (Recent Filing)$1.30M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Aug 19, 2025EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding119,961,450
10 Day Avg. Volume3,481,238
30 Day Avg. Volume2,109,643
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.05
Price to Sales (P/S)0.00
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.00Price Target Upside1328.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Invivyd News
PremiumCompany Announcements
Invivyd Reports Q1 2025 Financial Results and Outlook
PremiumCompany Announcements
Invivyd’s Earnings Call: Strategic Moves Amid Challenges
PremiumCompany Announcements
Invivyd Reports Q1 2025 Financial Results and Highlights---
Bulls Say, Bears Say
Bulls Say
Clinical DataLong-term data from the Phase 3 trial reported a 76% risk reduction in symptomatic COVID-19 over 12 months in immunocompetent individuals, suggesting broad protective durability.
Financial PerformanceNet revenue from PEMGARDA rose 48% sequentially in 4Q24, reflecting growing prescriber adoption and renewed confidence.
Bears Say
Regulatory ChallengesThe FDA has rejected Invivyd’s submission to expand PEMGARDA's Emergency Use Authorization to include COVID-19 treatment.
Sales PerformanceThe slower-than-expected ramp-up of PEMGARDA sales was attributed to an FDA update that created doubt and confusion among healthcare providers.
---
Ownership Overview
22.75% Insiders
7.53% Mutual Funds
<0.01% Other Institutional Investors
62.81% Public Companies and
Individual Investors
IVVD FAQ
What was Invivyd’s price range in the past 12 months?
Invivyd lowest stock price was $0.35 and its highest was $2.74 in the past 12 months.
What is Invivyd’s market cap?
Invivyd’s market cap is $100.28M.
When is Invivyd’s upcoming earnings report date?
Invivyd’s upcoming earnings report date is Aug 19, 2025 which is in 94 days.
How were Invivyd’s earnings last quarter?
Invivyd released its earnings results on May 15, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.03 by -$0.11.
Is Invivyd overvalued?
According to Wall Street analysts Invivyd’s price is currently Undervalued.
Does Invivyd pay dividends?
Invivyd does not currently pay dividends.
What is Invivyd’s EPS estimate?
Invivyd’s EPS estimate is -0.01.
How many shares outstanding does Invivyd have?
Invivyd has 119,961,450 shares outstanding.
What happened to Invivyd’s price movement after its last earnings report?
Invivyd reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.03. Following the earnings report the stock price went down -16.667%.
Which hedge fund is a major shareholder of Invivyd?
Currently, no hedge funds are holding shares in IVVD
---
Invivyd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (1328.57% Upside)
$10.00 (1328.57% Upside)
Blogger Sentiment
Bullish
IVVD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $130.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.38%
12-Months-Change
Fundamentals
Return on Equity
-138.71%
Trailing 12-Months
Asset Growth
-43.49%
Trailing 12-Months
Company Description
Invivyd
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
---
IVVD Company Deck
---
IVVD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted the successful internalization of the commercial team, pipeline expansion, and strong financial management. However, these positives were offset by a decline in Q1 revenue, regulatory hurdles with EUA expansion, and challenges in healthcare provider adoption. The company expressed confidence in its strategic direction and financial discipline but faces significant challenges in execution and regulatory approval.Read More>---
IVVD Stock 12 Month Forecast
Average Price Target
$10.00
▲(1328.57% Upside)
Technical Analysis
VistaGen Therapeutics
―
vTv Therapeutics
―
Clearside Biomedical
―
Jasper Therapeutics
―
Inozyme Pharma
―
---